The Future of Endocannabinoid Oriented Clinical Research After CB1 Antagonists

• $39.95
• 1 mg
• Link.springer.com

This scholarly commentary explores the future of clinical research centered around the endocannabinoid system following the development and use of CB1 receptor antagonists like rimonabant. Initially investigated for treating obesity and metabolic syndromes, these drugs have opened new pathways for understanding broader physiological impacts.